repaglinide krka
krka, d.d., novo mesto - repaglinide - diabetes mellitus, type 2 - drugs used in diabetes - repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (niddm)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.
terry white chemists metformin 1000 metformin hydrochloride 1000 mg tablet blister pack
apotex pty ltd - metformin hydrochloride -
chemmart metformin 1000 metformin hydrochloride 1000 mg tablet blister pack
apotex pty ltd - metformin hydrochloride -
repaglinide tablet
rising health, llc - repaglinide (unii: 668z8c33lu) (repaglinide - unii:668z8c33lu) - repaglinide 0.5 mg - repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitation of use: repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. repaglinide tablets are contraindicated in patients with: - concomitant use of gemfibrozil [see drug interactions (7)] - known hypersensitivity to repaglinide or any inactive ingredients risk summary limited available data from case reports and case series with repaglinide use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . teratogenicity was not observed in rats and rabbits administered repaglinide during organogenesis at approximately 60 and 1 times the maximum daily clinical dose, based on bod
repaglinide tablet
aurobindo pharma limited - repaglinide (unii: 668z8c33lu) (repaglinide - unii:668z8c33lu) - repaglinide 0.5 mg - repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitation of use: repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. repaglinide tablets are contraindicated in patients with: - concomitant use of gemfibrozil [see drug interactions (7)] - known hypersensitivity to repaglinide or any inactive ingredients risk summary limited available data from case reports and case series with repaglinide use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . teratogenicity was not observed in rats and rabbits administered repaglinide during organogenesis at approximately 60 and 1 times the maximum daily clinical dose, based on body surfac
repaglinide teva 0.5 mg
teva pharmaceutical industries ltd, israel - repaglinide - tablets - repaglinide 0.5 mg - repaglinide - repaglinide - treatment of type ii diabetes.
repaglinide teva 1 mg
teva pharmaceutical industries ltd, israel - repaglinide - tablets - repaglinide 1 mg - repaglinide - repaglinide - treatment of type ii diabetes.
metformin generichealth 1000 metformin hydrochloride 1000 mg tablet blister pack
generic health pty ltd - metformin hydrochloride -
repaglinide tablet
golden state medical supply, inc. - repaglinide (unii: 668z8c33lu) (repaglinide - unii:668z8c33lu) - repaglinide 0.5 mg - repaglinide tablets, usp (repaglinide) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitation of use: repaglinide tablets, usp (repaglinide) should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. repaglinide tablets is contraindicated in patients with: - concomitant use of gemfibrozil [see drug interactions (7.1)] - known hypersensitivity to repaglinide or any inactive ingredients risk summary limited available data from case reports and case series with repaglinide tablets use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy ( see clinical considerations ). teratogenicity was not observed in rats and rabbits administered repaglinide during organogenesis
repaglinide tablet
breckenridge pharmaceutical, inc. - repaglinide (unii: 668z8c33lu) (repaglinide - unii:668z8c33lu) - repaglinide 0.5 mg - repaglinide tablets, usp (repaglinide) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitation of use: repaglinide tablets, usp (repaglinide) should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. repaglinide tablets is contraindicated in patients with: - concomitant use of gemfibrozil [see drug interactions (7.1)] - known hypersensitivity to repaglinide or any inactive ingredients risk summary limited available data from case reports and case series with repaglinide tablets use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations ). teratogenicity was not observed in rats and rabbits administered repaglinide during organogenesis at approximately 60 and 1 times the maximum daily